You are here


Search Technologies

Showing 1-20 of 280 results found

3D Image Rendering Softwarefor Biological Tissues

The Frederick National Laboratory for Cancer Research seeks parties interested in collaborative research to co-develop software for the automatic 3-D visualization of biological image volumes.

A Gene-Based Prognostic for Hepatocellular Carcinoma Patient Response to Adjuvant Transcatheter Arterial Chemoembolization

The gold standard of care for hepatocellular carcinoma patients with intermediate- to locally advanced tumors is transcatheter arterial chemoembolization (TACE), a procedure whereby the tumor is targeted both with local chemotherapy and restriction of local blood supply. NCI scientists have identified a 14-gene signature predictive of response to TACE, and NCI seeks licensees or co-development partners to develop the technology toward commercialization.

A Mobile Health Platform

Researchers at the National Institute on Drug Abuse (NIDA) seek licensing or co-development of a mobile health technology that monitors and predicts a user’s psychological status in order to deliver an automated intervention when needed.

A multiple phase transitioning peptide hydrogel for use in vascular a

Researchers at the National Cancer Institute (NCI), in collaboration with surgical specialists from Johns Hopkins University, have developed hydrogel compositions and methods to suture blood vessels with the hydrogels during microsurgery. These hydrogels are particularly beneficial for surgeons in whole tissue transplant procedures. The NCI researchers seek licensing and/or co-development research collaborations for further development of this technology.

A New Class of Stable Heptamethine Cyanine Fluorophores and Biomedical Applications Thereof

Researchers at the National Cancer Institute (NCI) have developed an improved class of heptamethine cyanine fluorophore dyes useful for imaging applications in the near-IR range (750-850 nm). A new chemical reaction has been developed that provides easy access to novel molecules with improved properties. Specifically, the dyes display greater resistance to thiol nucleophiles, and are more robust while maintaining excellent optical properties. The dyes have been successfully employed in various in vivo imaging applications and in vitro labeling and microscopy applications. The NCI seek co-development or licensees to develop them as targetable agents for optical-guided surgical interventions.

A Rabbit Anti-pT1989 ATR Monoclonal Antibody for Use in Immunoassays

Researchers at the National Cancer Institute (NCI) have developed a monoclonal antibody against ataxia telangiectasia-mutated and Rad3-related (ATR) kinase phosphorylated at threonine 1989. The antibody can be used for pharmacodynamic assays to quantify drug action on the ATR target.

A Rapid Method of Isolating Neoantigen-specific T Cell Receptor Sequences

Recent research has demonstrated that neoantigen-specific T-cell receptors (TCRs) can be isolated from a cancer patient’s lymphocytes. These TCRs may be used to engineer populations of tumor-reactive T cells for cancer immunotherapies. Obtaining sequences of these functional TCRs is a critical initial step in preparing this type of personalized cancer treatment; however, current methods are time-consuming and labor-intensive. Scientists at the National Cancer Institute (NCI) have developed a rapid and robust method of isolating the sequences of mutation-specific TCRs to alleviate these issues; they seek licensing and/or co-development research collaborations for the development of a method for isolating the sequences of tumor-reactive TCRs. For collaboration opportunities, please contact Steven A. Rosenberg, M.D., Ph.D. at

A549 Cells: Lung Carcinoma Cell Line for Adenovirus

Scientists at the National Cancer Institute have developed a cell line designated A549 that was derived from explanted cultures of human lung cancer tissue. The A549 cell line has been tested under the guidance of the United States Food and Drug Administration (FDA) so, under current Good Manufacturing Practices (GMP), these cells may be suitable for use in manufacturing constructs for use in clinical trials. The National Cancer Institute seeks parties to non-exclusively license this research material.

Agonistic Human Monoclonal Antibodies against Death Receptor 4 (DR4)

The National Cancer Institute is seeking parties interested in licensing human monoclonal antibodies (mAbs) that bind to death receptor 4 ("DR4"). The tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and its functional receptors, DR4 and DR5, have been recognized as promising targets for cancer treatment.

Allele Specific shRNA for Nanog, and Its Use to Treat Cancer

The National Cancer Institute announced positive study results indicating that the expression of NanogP8, a pseudogene of Nanog, is upregulated in human colorectal cancer spheroids formed in serum-free medium. The National Cancer Institute's Labortory of Experimental Carcinogenesis seeks parties of interest to co-develop the use of shRNAs incorporated into a lentiviral vector as a gene therapy to inhibit NanogP8, a retrogene upregulated in several carcinomas.

Analogues of Withanolide E Sensitize Cancer Cells Toward Apoptosis

There is a need to develop compounds that can sensitize cancer cells to apoptosis inducing ligands, such as poly I:C and TRAIL. In collaboration with the University of Arizona, NCI investigators discovered a series of compounds in the withanolide family that synergistically enhance the response of cancer cells to treatment with an apoptosis-inducing ligand. The NCI seeks licensing and/or co-development research collaborations for development of withanolide E analogues for the treatment of cancer.

Angiogenesis-Based Cancer Therapeutic

The National Cancer Institute's Urologic Oncology Branch seeks interested parties to co-develop antagonists to VEGF-A and hepatocyte growth factor (HGF) that block signal transduction and associated cellular responses.

Anti-bacterial Treatments Using Peptide-Based Inhibitors of the STAT3-IL10 Pathway

Tuberculosis (TB) is an infectious disease that typically affects the lungs. Current therapies include a panel of antibiotics given over a range of 6-9 months. As a result of the expense of treatment, the extended timeframe needed for effective treatment, and the scarcity of medicines in some developing countries, patient compliance with TB treatment is very low and results in multi-drug resistant TB (MDR-TB). There remains a need for a faster, more effective treatment for TB. NCI researchers seek licensing and/or co-development of peptide inhibitors of STAT3 and IL-10 developed to treat bacterial infections such as tuberculosis. See aslo: NIH inventions E-164-2007 and E-167-2010